Interest in Oximunol Chewable Tablets from Chemaphor's Avivagen Animal Health subsidiary strong at American Animal Hospital Association/Ontario Veterinary Medical Association Conference
Avivagen Animal Health products showcased to 3500 veterinarians and technicians from Canada and the United States
OTTAWA, ONTARIO, April 6, 2011 - Traffic was brisk at the Avivagen Animal Health booth at the recent American Animal Hospital Association/Ontario Veterinary Medical Association (AAHA/OVMA) Conference held in Toronto, Ontario as about 3500 veterinarians, veterinary technicians and animal health professionals were introduced to Avivagen Animal Health Inc. (Avivagen) and its new products Oximunol™ Chewable Tablets and VetStem RC Regenerative Cell Therapy.
"One vet told us we were the talk of the show," commented Dave Hankinson, CEO of Avivagen Animal Health. "Others told us that they had seen our advertising in various veterinary publications and wanted to know more about our products."
"Participation in this show produced hundreds of leads as well as several product bookings for Oximunol™Chewable Tablets and the VetStem RC Regenerative Cell Therapy," said Stephanie Crisp, sales representative with Avivagen based in Toronto, Ontario. "We will be following up with the leads generated in the coming weeks."
A constant stream of veterinarians visited the booth and discussed the products at length with Avivagen sales reps and Avivagen Technical Veterinarian, Isabelle Verzberger-Epshtein, on hand to discuss the science behind the products and answer questions one on one.
The Avivagen booth also drew the attention of the media at the show, resulting in two interviews given by Dr. Verzberger-Epshtein to Canadian Pets and Animals Magazine and Carl Milton with Touch of Love, which will air segments in the future on CTV's Paws for News.
The AAHA/OVMA Conference was a joint effort this year of the American Animal Hospital Association and the Ontario Veterinary Medical Association resulting in exposure to both the American and Canadian animal health markets.
"Exposure to the American audience was key at this tradeshow," says Hankinson, "because we are actively working with partners in the US to launch Oximunol™ Chewable Tablets in that market this year."
The AAHA/OVMA Conference was the second of numerous key tradeshows planned this year for Avivagen. Other major tradeshows booked include the Association des médecins vétérinaries du Québec, in Saint-Hyacinthe, QC, the Canadian Veterinary Medical Association Conference in Halifax, NS, the Animal Health Technologists Association of British Columbia Conference in Kamloops, BC and the CanWest Veterinary Conference in Banff, AB. In February, Avivagen exhibited at the Ontario Association of Veterinary Technicians conference in London, ON.
Oximunol™ Chewable Tablets contain OxC-beta, a fully oxidized form of ß-carotene, that is made up of compounds occurring naturally in the plant world. These compounds offer significant health benefits to dogs in a palatable, chewable daily tablet. Canadian clinical trials submitted for publication have shown a statistically significant improvement in coat quality, including a reduction of shedding. Oximunol™ Chewable Tablets also help dogs enjoy activity more and help optimize normal gastrointestinal and general health, especially in older and less active dogs.
VetStem RC Regenerative Cell Therapy is scientifically proven for treatment of arthritic conditions, and joint and ligament injuries in dogs, cats and horses. The therapy uses regenerative cells derived from an animal's own adipose tissue. A small amount of fat tissue is extracted by the patient's veterinarian, and then couriered to Avivagen Animal Health's new, state-of-the-art, Canadian laboratory facility in Charlottetown, PEI. The cells are processed and counted, following stringent sterility and quality assurance guidelines. The doses required for immediate treatment are then returned to the veterinarian for injection into the patient, often within 48 hours of extraction. Extra doses are stored by Avivagen Animal Health for future treatments.
Avivagen is a new Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials and sold exclusively through veterinarians. Avivagen is a subsidiary of Chemaphor Inc., a Canadian company dedicated to the research and development of science-based, natural products for people and animals. VetStem RC Regenerative Cell Therapy has been exclusively licensed by Avivagen for the Canadian animal health market from Vet-Stem (USA).
Chemaphor is listed on the TSX Venture Exchange and trades under the symbol CFR.
###
For more information:
David Hankinson Graham Burton, PhD CEO, Avivagen Animal Health Inc. President and Co-Founder, Chemaphor Inc. Phone: 902-825-9270 Phone: 613-990-0969 d.hankinson@chemaphor.com g.burton@chemaphor.com
Investor Relations: Media Group
Evolution Group Inc. McCormick Global Communications Sylvain Archambault Karen Sample 514-448-4887 / Toll free: 866-703-4887 Phone: 519-475-6378 s.archambault@evolutiongrp.com ksample@mccormickglobal.com www.evolutiongrp.com
TM Trademark of Chemaphor Inc. VetStem RC Regenerative Cell Therapy is licensed from Vet-Stem, Inc.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above. Anyone interested in the treatments described above should discuss the potential benefits and risks of such treatments with their veterinarian. The interest expressed by Conference attendees and the leads described above may not translate into orders for products.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.